21 completed. 21 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 21 | Completed 21 |
| Phase 2 | 2 | Completed 2 |
Follow Relapsing Multiple Sclerosis: new trials by email Literature Review of Relapsing Multiple Sclerosis trials Research Report on Relapsing Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis Ocrelizumab IV, Ocrelizumab SC, Methylprednisolone IV - Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis | Phase 3 | Completed | Hoffmann-La Roche | 236 | 2022-05-03 | 2026-08-11 |
| A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis CNM-Au8 - Relapsing Multiple Sclerosis | Phase 2 / Phase 3 | Completed | Clene Nanomedicine | 55 | 2020-10-22 | 2023-12-08 |
| A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis Ofatumumab - Relapsing Multiple Sclerosis | Phase 3 | Completed | Novartis Pharmaceuticals | 111 | 2020-10-19 | 2026-01-13 |
| 9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis Ofatumumab, [F-18]PBR06 - Relapsing Multiple Sclerosis | Phase 3 | Completed | Brigham and Women's Hospital | 10 | 2020-09-21 | 2026-01-27 |
| An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab Ofatumumab - Relapsing Multiple Sclerosis | Phase 3 | Completed | Novartis Pharmaceuticals | 562 | 2020-07-14 | 2026-04-09 |
| Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1) Tolebrutinib, Teriflunomide, Placebo to match Tolebrutinib - Relapsing Multiple Sclerosis | Phase 3 | Completed | Sanofi | 974 | 2020-06-30 | 2025-07-02 |
| Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2) Tolebrutinib, Teriflunomide HMR1726, Placebo to match Tolebrutinib - Relapsing Multiple Sclerosis | Phase 3 | Completed | Sanofi | 899 | 2020-06-11 | 2025-07-02 |
| Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) Rituximab, Cladribine - Relapsing Multiple Sclerosis, Multiple Sclerosis | Phase 3 | Completed | Oslo University Hospital | 267 | 2019-10-16 | 2024-12-16 |
| Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients Siponimod - Multiple Sclerosis, Relapsing Multiple Sclerosis | Phase 3 | Completed | Novartis Pharmaceuticals | 185 | 2019-02-14 | 2024-06-20 |
| Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis Ofatumumab subcutaneous injection, Teriflunomide-matching placebo capsules, Teriflunomide capsule - Relapsing Multiple Sclerosis | Phase 3 | Completed | Novartis Pharmaceuticals | 930 | 2016-09-20 | 2021-10-01 |
| Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis Ozanimod, Ozanimod placebo, Interferon beta-1a - Relapsing Multiple Sclerosis | Phase 3 | Completed | Celgene | 1320 | 2013-12-03 | 2021-02-11 |
| Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017) BIIB017, naproxen - Relapsing Multiple Sclerosis | Phase 3 | Completed | Biogen | 251 | 2013-11-01 | 2017-01-25 |
| Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients Ozanimod, Placebo - Relapsing Multiple Sclerosis | Phase 2 / Phase 3 | Completed | Celgene | 258 | 2012-09-18 | 2021-02-11 |
| A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis Interferon beta-1a, Ocrelizumab-matching placebo, Ocrelizumab - Relapsing Multiple Sclerosis | Phase 3 | Completed | Hoffmann-La Roche | 835 | 2011-09-20 | 2024-03-08 |
| A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis Interferon beta-1a, Ocrelizumab-matching placebo, Ocrelizumab - Relapsing Multiple Sclerosis | Phase 3 | Completed | Hoffmann-La Roche | 821 | 2011-08-31 | 2024-03-04 |
| Long-Term Safety and Efficacy Study of Peginterferon Beta-1a peginterferon beta-1a - Relapsing Multiple Sclerosis | Phase 3 | Completed | Biogen | 1077 | 2011-04-01 | 2017-01-13 |
| Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS) Fingolimod, Placebo, Seasonal influenza vaccine - Relapsing Multiple Sclerosis | Phase 3 | Completed | Novartis | 138 | 2010-08-01 | 2012-06-19 |
| Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients FTY720 - Relapsing Multiple Sclerosis | Phase 3 | Completed | Novartis | 2417 | 2010-05-01 | 2017-02-23 |
| Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis BIIB017 (peginterferon beta-1a), Placebo - Relapsing Multiple Sclerosis | Phase 3 | Completed | Biogen | 1516 | 2009-06-01 | 2014-09-19 |
| Transition to Rebif New Formulation Rebif New Formulation + prophylactic Ibuprofen, Rebif New Formulation + ibuprofen PRN - Relapsing Multiple Sclerosis | Phase 3 | Completed | Merck KGaA, Darmstadt, Germany | 117 | 2007-07-01 | 2014-02-27 |
Showing 20 of 21. Sign in to see all of them.
Multiple Sclerosis (6) · Recurrence (3) · Demyelinating Diseases (1) · Multiple Sclerosis, Chronic Progressive (1) · Optic Nerve Diseases (1) · Optic Neuritis (1)
Autoimmune Diseases (7) · Autoimmune Diseases of the Nervous System (7) · Demyelinating Autoimmune Diseases, CNS (7) · Immune System Diseases (7) · Nervous System Diseases (7) · Demyelinating Diseases (6) · Disease Attributes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Chronic Disease (1) · Cranial Nerve Diseases (1) · Eye Diseases (1) · Multiple Sclerosis (1)
Interferon beta-1a (3) · ofatumumab (3) · peginterferon beta-1a (3) · teriflunomide (3) · Fingolimod Hydrochloride (2) · ocrelizumab (2) · ozanimod (2) · Anti-Inflammatory Agents, Non-Steroidal (1) · Cladribine (1) · Ibuprofen (1) · N-fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline (1) · Naproxen (1) · Rituximab (1) · Tetanus Toxoid (1) · siponimod (1)
Novartis Pharmaceuticals (4) · Biogen (3) · Hoffmann-La Roche (3) · Celgene (2) · Novartis (2) · Sanofi (2) · Brigham and Women's Hospital (1) · Clene Nanomedicine (1) · EMD Serono (1) · Merck KGaA, Darmstadt, Germany (1) · Oslo University Hospital (1)
United States (16) · Spain (13) · Poland (12) · Belgium (11) · Russia (11) · Canada (10) · Czechia (10) · Germany (10) · United Kingdom (10) · Bulgaria (9) · Italy (9) · France (8) · Greece (8) · Ukraine (8) · Hungary (7)
Fernando Dangond, MD (1) · Gro Owren Nygaard, MD, PhD (1) · Hanne Flistad Harbo, MD, PhD (1) · Sabine Latour, MD (1) · Tarun Singhal, MD (1)
PMID 37652990, PMID 28002679, PMID 32511687, PMID 32690791, PMID 33724637, PMID 34904871, PMID 35672926, PMID 36163349, PMID 36792367, PMID 37148240, PMID 39290861, PMID 39965438, PMID 40202623, PMID 40258203, PMID 40554392, PMID 40629721, PMID 42546561, PMID 42832215, PMID 24221641, PMID 24794721, PMID 25073663, PMID 25265472, PMID 25432952, PMID 25551571, PMID 26195056, PMID 26879276, PMID 28183276, PMID 28450894, PMID 28607743, PMID 29104758, PMID 30043658, PMID 30181780, PMID 31492652, PMID 32757523, PMID 33307998, PMID 35266417, PMID 37094998, PMID 37606897, PMID 39018512, PMID 39460719, PMID 40245351, PMID 40248858, PMID 40462564, PMID 41196386, PMID 42371147
2008 (1), 2015 (1), 2019 (1)